We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division


HemoCue AB develops, produces, and markets medical diagnostic products for point of care testing (POC) markets. Its p... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Dengue Patients’ Hemoglobin Concentrations Compared by POC and CBC

By LabMedica International staff writers
Posted on 06 Sep 2021
Print article
Image: The HemoCue Hb 201+ System Analyzer has become a standard in hemoglobin point-of-care testing (Photo courtesy of HemoCue AB)
Image: The HemoCue Hb 201+ System Analyzer has become a standard in hemoglobin point-of-care testing (Photo courtesy of HemoCue AB)
Dengue is a mosquito-borne viral infection that is mainly found in tropical and sub-tropical climates. The natural history of dengue has the unique characteristic of plasma leakage that results in hemoconcentration as well as vasculopathy and thrombocytopenia that result in bleeding.

Hematocrit monitoring is a crucial tool to guide management in dengue patients. Microhematocrit adjunct with a complete blood count (CBC) to monitor dengue patients were traditionally performed to decrease the frequency of venipuncture. However, microhematocrit is currently less preferred to the point-of-care hemoglobin monitoring tools to measure red cells in other diseases.

A team of medical scientists at the Ramathibodi Hospital (Bangkok, Thailand) evaluated the relationship between hemoglobin measured by point-of-care hemoglobin (POC-Hb) testing and hematocrit measured by the automated method in adult dengue patients. A total of 44 dengue patients were enrolled. Twenty-nine patients (65.9%) were female, with a median age of 31 years (interquartile range 22–41). Of the enrolled patients, 30 (68.2%), 11 (25.0%), and three (6.8%) were classified as dengue without warning signs, with warning signs, and severe dengue, respectively. Seven patients (15.9%) had hemoconcentration, and five patients (11.3%) had bleeding.

The team measured a CBC by Mindray BC-6800Plus (Mindray, Shenzhen, China) at Ramathibodi Hospital, and Sysmex XN-3000 (Sysmex, Kobe, Japan) at Chakri Naruebodindra Medical Institute. POC-Hb testing was performed on capillary blood and read by the HemoCue Hb 201+ (HemoCue AB, Ängelholm, Sweden). POC-Hb testing was conducted by three physicians who were trained on the use of the device. Hemoconcentration was defined by an increase of ≥20% in hematocrit compared with a convalescent value. A total of 216 pairs of POC-Hb and CBC were evaluated.

The investigators reported that the medians of hemoglobin and hematocrit at dengue presentation were 13.8 g/dL and 41.6%, respectively. The medians of mean corpuscular volume (MCV) and platelets were 87.0 fL and 98,500/mm3, respectively. The team found a significant positive correlation was observed between hemoglobin measured by POC-Hb testing and hematocrit measured by an automated CBC. Bland-Altman analysis between hemoglobin measured by POC-Hb testing and an automated CBC showed a bias of -0.43. Using the cutoff of POC-Hb ≥20% as a criteria for hemoconcentration, the sensitivity and specificity of hemoconcentration detected by POC-Hb device were 71.4% and 100.0%, respectively.

The authors concluded that hemoglobin measurement using POC-Hb testing adjunct with CBC monitoring can be used to monitor plasma leakage as well as hemorrhage in dengue patients. The use of POC-Hb testing is less invasive and requires less blood compared to venipuncture for CBC evaluation. The study was published on August 16, 2021 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Ramathibodi Hospital
HemoCue AB

Gold Supplier
ADAMTS13 Activity Assay
HemosIL ACUSTAR ADAMTS13 Activity Assay
Next-Generation Sequencing Platform
Clear Dx
Giardia, Cryptosporidium and E. Histolytica Antigen Test
Clinical Chemistry Analyzer
Mispa CXL Pro

Print article



view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.